Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Abivax SA Sponsored ADR (ABVX – Research Report). The associated price target remains the same with $45.00.
Sam Slutsky’s rating is based on several promising aspects of Abivax’s current and future prospects. The company is making significant progress with its clinical studies for obefazimod, an oral splicing modulator aimed at treating inflammatory bowel disease. The Phase 3 induction data for moderate-to-severely active ulcerative colitis is expected in Q3 2025, and this milestone could act as a major catalyst for the company’s stock, potentially leading to a substantial increase in its value.
Additionally, Abivax’s financial position appears robust, with €144.2 million in cash at the end of 2024, which is anticipated to support operations until after the Phase 3 data release. Despite reporting a net loss in 2024, the company’s focus on advancing its clinical programs and the potential for positive outcomes from its studies contribute to the optimistic outlook. These factors combined support Sam Slutsky’s Buy rating for Abivax SA Sponsored ADR.
In another report released yesterday, BTIG also maintained a Buy rating on the stock with a $43.00 price target.